No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina / NY / Florida       

Pie Medical Imaging Announces FASTIII, a Multicenter Randomized Clinical Trial

Trial will investigate the use of angiography-based vessel fractional flow reserve (CAAS vFFR) in patients undergoing coronary revascularization procedures

Editor: What To Know

  • The high diagnostic accuracy of CAAS vFFR, which calculates pressure drop and vFFR value using angiography images only was recently confirmed by the results of FAST I, FAST Extend and FASTII studies which validated vFFR as an accurate and easy to use tool to assess coronary physiology.
  • The FAST III study aims to demonstrate non-inferiority of CAAS vFFR guided revascularization as compared to a conventional invasive wire based FFR guided revascularization in patients with either stable coronary syndrome or non-ST segment elevation myocardial infarction and intermediate coronary artery lesions.
  • Joost Daemen (cardiologist at the Thoraxcenter at the Erasmus University Medical Center, Rotterdam, The Netherlands), is an investigator initiated international, multi-center randomized, non-inferiority trial aiming to enroll a total of 2228 patients, in 7 European countries and  35 hospitals and is sponsored by the European Cardiovascular Research Institute (ECRI).

Pie Medical Imaging (“PMI”), (cardiac imaging), part of the Esaote Group, today announced the beginning of FASTIII, a multicenter randomized clinical trial that will investigate the use of angiography-based vessel fractional flow reserve (CAAS vFFR) in patients undergoing coronary revascularization procedures.

The FASTIII trial, that is led by Dr. Joost Daemen (cardiologist at the Thoraxcenter at the Erasmus University Medical Center, Rotterdam, The Netherlands), is an investigator initiated international, multi-center randomized, non-inferiority trial aiming to enroll a total of 2228 patients, in 7 European countries and  35 hospitals and is sponsored by the European Cardiovascular Research Institute (ECRI).

The FAST III study aims to demonstrate non-inferiority of CAAS vFFR guided revascularization as compared to a conventional invasive wire based FFR guided revascularization in patients with either stable coronary syndrome or non-ST segment elevation myocardial infarction and intermediate coronary artery lesions.

vFFR can assess whether a coronary artery narrowing is functionally severe and requires treatment. CAAS vFFR allows doing so without the need of invasive wires- that are part of the routine practice to measure pressure gradients (FFR) – and adenosine.

The high diagnostic accuracy of CAAS vFFR, which calculates pressure drop and vFFR value using angiography images only was recently confirmed by the results of FAST I, FAST Extend and FASTII studies which validated vFFR as an accurate and easy to use tool to assess coronary physiology.

“We are confident that this new study will lead to a broader use of methods based on angiographic images for a safe and accurate assessment of severity and percentage of artery stenosis” said René Guillaume, PMI Managing Director.

The trial is funded by research grants from Pie Medical Imaging (Maastricht, the Netherlands) and Siemens Healthineers GmbH (Erlangen, Germany).

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy